An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
4 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.
Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.